Efrax SRL
The score of Efrax shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity +27 % Total assets +4 %
Accounts of the company itself (not consolidated).
The full file covers 9 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Efrax's annual accounts
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net result | 45,359 € | ||||
| Equity | 438,324 € | ||||
| Cash | 141,984 € | ||||
| EBITDA | 63,837 € | ||||
| Total assets | 577,651 € |
Filed annual accounts
- Year ended 30 Sep 2025filed on 04 Mar 2026
- Year ended 30 Sep 2024filed on 04 Mar 2025
- Year ended 30 Sep 2023filed on 11 Mar 2024
- Year ended 30 Sep 2022filed on 14 Mar 2023
- Year ended 30 Sep 2021filed on 08 Mar 2022
Efrax's financial analysis
- Solvency75.9%sector median: 50.3%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Efrax
Efrax's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0654.897.577
- VAT number
- BE0654897577
- Peppol
- Registered · 0208:0654897577 · as of 08 Nov 2026
- Legal form
- SRL
- Incorporated
- 23 May 2016
- Registered office
- 2930 Brasschaat
- Latest accounts
- 2025 · filed on 04 Mar 2026
- Activity
- Manufacture of other pharmaceutical products (NACE 21209)
Efrax (SRL) has been based in Brasschaat since 2016, active in: manufacture of other pharmaceutical products. For 2025, it reports a net profit of 45,359 € and equity of 438,324 €; its revenue is not published. Its solvency stands at 75.9%, above the median of its sector (50.3%).
Companies similar to Efrax
Companies in the same business, of comparable size and area, outside its group.
- APR Pharma Manufacture of basic pharmaceutical products Courcelles · balance sheet 244,955 €
- Romali Activities of holding companies Zonhoven · balance sheet 582,043 €
- Joos Clinical Projects Manufacture of basic pharmaceutical products Destelbergen · balance sheet 549,074 €
- Lotte Scheldeman Retail sale of pharmaceutical products Bornem · balance sheet 742,475 €
- Lidefarma Retail sale of pharmaceutical products Lierde · balance sheet 495,027 €
- Electro-Cap Center Wholesale of pharmaceutical and medical goods Kapellen · balance sheet 909,917 €
- Medys Wholesale of pharmaceutical and medical goods Kapellen · balance sheet 774,225 €
- Prieels Pharma Retail sale of pharmaceutical products Oud-Heverlee · balance sheet €1.29m
Frequently asked questions about Efrax
What is the revenue of Efrax?
Efrax files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Efrax?
In Belgium, the VAT number is the company number prefixed with BE: BE0654897577 for Efrax, if the company is VAT-registered. Its company number (CBE) is 0654.897.577.
Where is the registered office of Efrax?
According to the CBE register, the registered office of Efrax is in 2930 Brasschaat.
What is the equity of Efrax?
At the close of the 2025 financial year, the equity of Efrax amounts to 438,324 €, a solvency of 75.9% of total assets.
Who manages Efrax?
The register lists 2 active mandates at Efrax. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Efrax
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →